10-Q 1 f10q0322_bespoke.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: March 31, 2022

 

or

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 000-52759

 

BESPOKE EXTRACTS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   20-4743354
(State or other jurisdiction 
of incorporation)
  (IRS Employer 
Identification No.)

 

2590 Walnut St.

DenverCO 80205

(Address of principal executive offices)

 

855-633-3738

(Registrant’s telephone number, including area code)

  

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No

 

As of May 16, 2022, there were 417,131,119 shares outstanding of the registrant’s common stock, par value $0.001.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page No. 
     
PART I - FINANCIAL INFORMATION 1
Item 1. Financial Statements 1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
Item 3. Quantitative and Qualitative Disclosures About Market Risk 18
Item 4 Controls and Procedures 18
     
PART II - OTHER INFORMATION 19
Item 1. Legal Proceedings 19
Item 1A. Risk Factors 19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19
Item 3. Defaults Upon Senior Securities 19
Item 4. Mine Safety Disclosures 19
Item 5. Other Information 19
Item 6.

Exhibits

19

 

i

 

 

PART I

 

Item 1. Financial Statements. 

 

Bespoke Extracts, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

(Unaudited)

 

   March 31,   December 31, 
   2022   2021 
         
Assets        
Current assets        
Cash  $94,331   $148,227 
Accounts receivable, net   3,700    3,636 
Advances to WonderLeaf   6,443    
-
 
Note receivable and accrued interest WonderLeaf   20,181    
-
 
Prepaid expense   5,443    6,439 
Inventory, net   46,470    46,825 
Total current assets   176,568    205,127 
           
Furniture and equipment   9,947    2,745 
Right of Use Asset   324,035    339,780 
Deposits   12,000    12,000 
Total assets  $522,550   $559,652 
           
Liabilities and Stockholders’ Equity          
Current liabilities          
Accounts payable and accrued liabilities  $105,621   $82,729 
Inventory earn-out   75,000    75,000 
Note payable - related party   
-
    2,500 
Operating lease liability   61,279    59,777 
Total current liabilities   241,900    220,006 
           
Long-Term Operating Lease Liability   264,219    280,369 
Total liabilities   506,119    500,375 
           
Commitments and contingencies (Note 10)   
 
    
 
 
           
Stockholders’ Equity          
Preferred stock, par value $0.001, 50,000,000 shares authorized, 1 share issued and outstanding as of March 31, 2022 and December 31, 2021, respectively   
-
    
-
 
Series C Preferred Stock, $0.001 par value, 1 share designated; 1 share issued and outstanding as of March 31, 2022 and December 31, 2021, respectively, stated value $24,000   
-
    
-
 
Common stock, $0.001 par value: 3,000,000,000 shares authorized; 406,129,924 and 366,679,924 shares issued and 338,629,924 and 299,179,924 shares outstanding as of March 31, 2022 and December 31, 2021, respectively   338,630    299,180 
Additional paid-in capital   20,417,867    19,527,669 
Accumulated deficit   (20,740,066)   (19,767,572)
Total stockholders’ equity   16,431    59,277 
Total liabilities and stockholders’ equity  $522,550   $559,652 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

Bespoke Extracts, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(Unaudited)

 

   For the Three Months Ended 
   March 31,   March 31, 
   2022   2021 
         
Sales  $3,061   $5,748 
Cost of products sold   847    1,368 
Gross Profit   2,214    4,380 
           
Operating expenses:          
Selling, general and administrative expenses   897,534    191,861 
Professional fees   54,355    21,343 
Consulting   23,000    71,500 
Amortization expense of domain name   
-
    811 
Total operating expenses   974,889    285,515 
           
Loss from operations   (972,675)   (281,135)
           
Other income          
Interest income   181    
-
 
Total other income   181    
-
 
           
Loss before income tax   (972,494)   (281,135)
Provision for income tax   
-
    
-
 
Net Loss  $(972,494)  $(281,135)
           
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING          
Basic and Diluted   314,643,146    240,532,826 
           
NET LOSS PER COMMON SHARE OUTSTANDING          
Basic and Diluted  $(0.00)  $(0.00)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

Bespoke Extracts, Inc. and Subsidiary

Condensed consolidated Statement of Stockholders Equity / (Deficit)

For The Three Months Ended March 31, 2022 and 2021

(Unaudited)

 

   Series C                         
   Preferred   Preferred   Common   Common   Additional   Common         
   Shares   Par   Shares   Par   Paid-in   Stock   Accumulated     
   Outstanding   Amount   Outstanding   Amount   Capital   Payable   Deficit   Total 
Balance December 31, 2020 (Unaudited)          1   $
       -
    229,388,426   $229,389   $18,307,635   $76,000   $(19,115,950)  $(502,926)
                                         
Common stock for conversion of note payable - related party   -    
-
    5,000,000    5,000    95,000    
-
    
-
    100,000 
                                         
Sale of common stock   -    
-
    12,000,000    12,000    588,000    
-
    
-
    600,000 
                                         
Issuance of common stock payable   -    
-
    500,000    500    75,500    (76,000)   
-
    
-
 
                                         
Net loss for the three months ended March 31, 2021   -    
-
    -    
-
    
-
    
-
    (281,135)   (281,135)
Balance  March 31, 2021 (Unaudited)   1   $
-
    246,888,426   $246,889   $19,066,135   $
-
   $(19,397,085)  $(84,061)

 

   Series C                     
   Preferred   Preferred   Common   Common   Additional         
   Shares   Par   Shares   Par   Paid-in   Accumulated     
   Outstanding   Amount   Outstanding   Amount   Capital   Deficit   Total 
Balance December 31, 2021 (Unaudited)          1   $
       -
    299,179,924   $299,180   $19,527,669   $(19,767,572)  $59,277 
                                    
Payment of capital contribution   -    
-
    -    
-
    4,792    
-
    4,792 
                                    
Stock based compensation and stock option expense   -    
-
              727,606    
-
    727,606 
                                    
Unit Offering   -    
-
    39,450,000    39,450    157,800    
-
    197,250 
                                    
Net loss for the three months ended March 31, 2022   -    
-
    -    
-
    
-
    (972,494)   (972,494)
Balance March 31, 2022 (Unaudited)   1   $
-
    338,629,924   $338,630   $20,417,867   $(20,740,066)  $16,431 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

Bespoke Extracts, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

   For the Three Months Ended 
   March 31,   March 31, 
   2022   2021 
Cash flows from operating activities        
Net Loss  $(972,494)  $(281,135)
Adjustments to reconcile net loss to net cash used in operating activities          
Amortization expense of domain names   
-
    811 
Amortization of Right of Use Asset   15,745    3,061 
Stock based compensation and stock option expense   727,606    
-
 
Changes in operating assets and liabilities:          
Accounts receivable   (64)   (1,230)
Prepaid expense   996    (80,661)
Inventory   355    (6,207)
Interest receivable WonderLeaf   (181)   
-
 
Operating lease liability   (14,648)   
-
 
Accounts payable and accrued liabilities   22,892    29,862 
Net Cash used in operating activities   (219,793)   (335,499)
           
Cash flows from investing activities          
Advances to WonderLeaf   (6,443)     
Payments to Note receivable WonderLeaf   (20,000)   
-
 
Purchase of equipment   (7,202)   
-
 
Net cash used in investing activities   (33,645)   
-
 
           
Cash flow from financing activities          
Payment of capital contribution   4,792    
-
 
Repayment of note payable - related party   (2,500)   
-
 
Proceeds from the issuance of units   197,250    600,000 
Net cash provided by financing activities   199,542    600,000 
           
Net increase / (decrease) in cash   (53,896)   264,501 
Cash at beginning of period   148,227    79,795 
Cash at end of period  $94,331   $344,296 
           
Supplemental disclosure of cash flow information          
Cash paid for interest  $
-
   $
-
 
Cash paid for income taxes  $
-
   $
-
 
           
Noncash investing and financing activities:          
Stock issued for conversion of debt - related party  $
-
   $100,000 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

BESPOKE EXTRACTS, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2022

(Unaudited)

 

1. NATURE OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

 

Nature of Business Operations 

 

Bespoke Extracts, Inc. (the “Company”) is a Nevada corporation focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.

 

In November 2021, new management of the Company was appointed and the Company began to focus on other complimentary lines of business to its CBD offerings. Under our new management team, we plan to expand the Company’s focus to regulated cannabis markets in the United States.

 

On December 2, 2021, Bespoke Extracts Colorado, LLC (“Bespoke Colorado”), a newly formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, LLC (“WonderLeaf”), and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the “WonderLeaf Purchase Agreement”). Pursuant to the Wonderleaf Purchase Agreement, Bespoke Colorado agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth in the Wonderleaf Purchase Agreement, for a purchase price of $225,000, to be paid in shares of common stock of the Company (including 2,500,000 shares issuable, and to be held in escrow, upon execution of the WonderLeaf Purchase Agreement, and an additional $150,000 of common stock that will be valued based on the volume weighted average price of the common stock, subject to a floor of $0.02 per share and a ceiling of $0.04 per share), provided that, the purchase price for the inventory will be 90% of the wholesale value of the regulated marijuana portion of the inventory and the packaging corresponding thereto set forth on the inventory accounting statement to be prepared pursuant to the Wonderleaf Purchase Agreement. As of the date of filing the Company has not closed on the transaction.

 

Basis of Presentation

 

The accompanying condensed consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments of a normal and recurring nature considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022 may not necessarily be indicative of the results that may be expected for the year ended December 31, 2022.

 

For further information, refer to the Company’s financial statements and footnotes thereto included in the Annual Report on Form 10-K for the year ended August 31, 2021 and the Transition Report on Form 10Q-T for the transition period from September 1, 2021 to December 31, 2021.

 

On February 2, 2022, the Company changed its fiscal year from August 31 to December 31.

 

Certain prior period amounts have been reclassified to conform to the current period presentation.

 

Principles of Consolidation

 

The accompanying condensed consolidated unaudited financial statements include the accounts of Bespoke Extracts, Inc., and its wholly owned subsidiary Bespoke Extracts Colorado, LLC. All inter-company balances have been eliminated.

 

5

 

 

Going Concern

 

The accompanying condensed consolidated unaudited financial statements have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations, a working capital deficit and an accumulated deficit as of and for the three months ended March 31, 2022. This raises substantial doubt about our ability to continue as a going concern.

 

The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed.

 

Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail or cease our operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. These financial statements do not include any adjustments that might arise from this uncertainty.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements and accompanying notes. Significant estimates include the assumption used in the valuation of equity-based transactions, valuation of intangible assets, allowance for doubtful accounts and inventory valuation and reserves. Actual results could differ from those estimates. 

 

Cash and Cash Equivalents

 

Cash and cash equivalents include all highly liquid investments with original maturities of three months or less at the time of purchase. At March 31, 2022 and December 31, 2021, the Company did not have any cash equivalents.

 

Fair Value of Financial Instruments

 

The carrying amounts of cash, accounts receivable, prepaid expenses, inventory and other assets, accounts payable, accrued liabilities, note payable and convertible note payable approximate their fair values as of March 31, 2022 and December 31, 2021, respectively, because of their short-term natures and the Company’s borrowing rate of interest.

 

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.

 

The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. At March 31, 2022 and December 31, 2021, the Company has recorded an allowance for doubtful accounts of $0 and $0, respectively. At March 31, 2022 and December 31, 2021 included in the accounts receivable is the merchant holdback receivable balance of $3,636 and $3,636, respectively which will be remitted to the Company in the future.

 

6

 

 

Advances to WonderLeaf

 

During the three months ended March 31, 2022 the Company advanced WonderLeaf $6,443 to cover operating expenses. The amounts are repayable upon demand.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of March 31, 2022 and December 31, 2021, inventory amounted to $46,470 and $46,825, respectively, which consisted of finished goods of $43,219 and $43,574, and raw materials of $3,251 and $3,251 net of reserves, respectively. As of March 31, 2022 and December 31, 2021 inventory reserves were $33,476 and $33,476, respectively.

 

Revenue Recognition

 

We account for revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification Topic 606, “Revenue from Contracts with Customers”. Revenue is measured based on the amount of consideration that we expect to receive, reduced by discounts and estimates for credits and returns (calculated based upon previous experience and management’s evaluation). Outbound shipping charged to customers is recognized at the time the related merchandise revenues are recognized and are included in net revenues. Inbound and outbound shipping and delivery costs are included in cost of revenues.

 

Our products are sold through our online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due on the date of shipment. The Company offers a 30 day return policy on sales.

 

Stock Based Compensation

 

Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance with FASB ASC 718, Compensation-Stock Compensation, including related amendments and interpretations.

 

Net Income / (Loss) per Share

 

Basic income / (loss) per share amounts are computed based on net income / (loss) divided by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. The effect of 25,333,500 warrants and 46,072,874 options is anti-dilutive for the three months ended March 31, 2022 as they are not in the money. The effect of 3,000,000 warrants and 0 options, as well as 500,000,000 shares issuable upon the conversion of a convertible note, is anti-dilutive for the three months ended March 31, 2021. 

 

Recent accounting pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date.

 

Income Taxes

 

We utilize the asset and liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.

 

7

 

 

2. ASSET PURCHASE AGREEMENT

 

On February 21, 2017, the Company purchased all right, title, interest and goodwill in or associated with certain domain names set forth in an asset purchase agreement for a total of $20,185 in cash and 200,000 shares of the Company’s common stock valued at $30,000. During the year ended August 31, 2020, the Company transferred certain URLs valued at $5,282 to an unrelated party and impaired $289 leaving a balance of $44,614 of URLs. The domain names are being amortized over a 15 year period. During the year ended August 31, 2021, the Company recorded an amortization expense of $3,244. During the year ended August 31, 2020, the Company recorded an impairment expense of $289 for the expired domain names. During the three months ended March 31, 2022 and 2021, the Company recorded an amortization expense of $0 and $811, respectively.

 

In connection with a stock purchase agreement (see note 7), on October 28, 2021, a convertible debenture with an original issue date of December 24, 2019, as amended by Amendment No. 1 thereto, dated May 28, 2020, Amendment No. 2 thereto, dated August 21, 2020, Amendment No. 3 thereto, dated December 10, 2020, Amendment No. 4 thereto, dated January 15, 2021, Amendment No. 5 thereto, dated April 2, 2021, and Amendment No. 6 thereto, dated August 2, 2021 (as amended, the “Debenture”) with an original principal amount of approximately $400,000 was terminated, and all amounts due and payable thereunder forgiven pursuant to a cancellation and satisfaction of debenture agreement entered into between the Company and the Debenture holder. In exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names valued at $32,748. (See Notes 3 and 6.)

 

3. INVENTORY EARN-OUT

 

As described in Notes 2 and 6, in exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names and agreed to pay the holder, beginning December 1, 2021, and on a monthly basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company, and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the monthly payments made under the Inventory Earn Out. As of March 31, 2022 no amounts have been paid.

 

4. NOTE RECEIVABLE

 

On January 19, 2022 the Company loaned WonderLeaf $10,000, pursuant to a promissory note. The note bears interest at 5.0% annually and matures on January 18, 2023. Accrued interest amounted to $111 at March 31, 2022.

 

On February 8, 2022 the Company loaned WonderLeaf $10,000, pursuant to a promissory note. The note bears interest at 5.0% annually and matures on February 8, 2023. Accrued interest amounted to $70 at March 31, 2022.

 

5. NOTE PAYABLE - RELATED PARTY

 

During the three months ended March 31, 2022, Michael Feinsod, the Company’s chief executive officer, was repaid $2,500.

  

8

 

 

6. CONVERTIBLE NOTE PAYABLE

 

On December 24, 2019, the Company entered into and closed a securities purchase agreement with an accredited investor, pursuant to which the Company issued and sold to the investor an original issue discount convertible debenture in the principal amount of $500,000, for a purchase price of $300,000. The Company also issued to the investor 5,000,000 shares of common stock valued at $55,000 ($0.005 per share). The Company recorded beneficial conversion of $245,000 due to the conversion feature. The debenture could not be converted to common stock to the extent such conversion would result in the holder beneficially owning more than 4.99% of the Company’s outstanding common stock. The debenture had an original maturity date of April 30, 2020 and was convertible into shares of common stock of the Company at an initial conversion price of $0.001, except that, if the Company failed to repay the debenture upon maturity, the conversion price would be reduced to $0.0004 (subject to adjustment for stock splits, stock dividends, and similar transactions) and the debenture would bear interest at the rate of 9% per year. The Company’s obligation to repay the debenture upon maturity was initially secured by a security interest in the Company’s inventory pursuant to a security agreement between the Company and the investor. For the year ended August 31, 2020 the Company recorded amortization of debt discount of $500,000. A portion of the debenture was subsequently sold by the original purchaser to a third party. On April 23, 2020, the Company entered into an amendment to the security agreement with the holders of the debentures. Pursuant to the security agreement amendment, the collateral under the security agreement was amended to be the Company’s URLs. The Company also entered into six amendments to the debentures, including to increase the conversion price to $0.05, and to extend the maturity date, including an amendment entered into on August 2, 2021, to extend the maturity date to August 31, 2021. In September 2021, a debenture holder converted $100,000 into 2,000,000 shares of common stock at a price of $0.05 per share. As of March 31, 2022, there is no convertible debt outstanding.

 

On October 28, 2021, in connection with a stock purchase agreement, the Debenture with an original principal amount of approximately $400,000 was terminated, and all amounts due and payable thereunder forgiven pursuant to a cancellation and satisfaction of debenture agreement entered into between the Company and the Debenture holder. In exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names valued at $32,748 and agreed to pay the holder, beginning December 1, 2021, and on a monthly basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company, and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the monthly payments made under the Inventory Earn Out. The Company recorded a gain on the extinguishment of debt $292,252

 

7. LEASES

 

In connection with the Wonderleaf Purchase Agreement, Bespoke Colorado entered into a lease agreement (the “Lease”) with WL Holdings, Ltd. (“WL Holdings”) Pursuant to the Lease, Bespoke Colorado will lease from WL Holdings certain commercial space in Aurora, Colorado, where WonderLeaf’s business has been located, commencing upon signing of the Lease and Wonderleaf Purchase Agreement, for a term of five years, which Bespoke Colorado will have an option to renew for an additional five years. Monthly rent under the Lease will start at $6,000. The Lease grants the Company an option to purchase the property for $600,000. The Company has not decided whether it will exercise either option.

 

Supplemental balance sheet information related to leases was as follows:

 

      March 31, 
Operating Leases  Classification  2022 
Right-of-use assets  Right of use assets  $324,035 
         
Current lease liabilities  Current operating lease liabilities   61,279 
Non-current lease liabilities  Long-term operating lease liabilities   264,219 
Total lease liabilities     $325,498 

 

Lease term and discount rate were as follows:

 

   December 31, 
   2021 
Weighted average remaining lease term (years)   4.67 
Weighted average discount rate   4%

 

9

 

 

The component of lease costs was as follows:

 

  

Three months
ended

March 31, 

 
   2022 
Operating lease cost  $19,098 
Variable lease cost (1)   1,050 
Total lease costs  $20,148 

 

(1) Variable lease cost primarily relates to common area maintenance, property taxes and insurance on leased real estate.

  

Supplemental disclosures of cash flow information related to leases were as follows:

 

   March  31, 
   2022 
Cash paid for operating lease liabilities  $18,000 

 

Maturities of lease liabilities were as follows as of December 31, 2021:

 

    Operating
 
    Leases 
2022   $54,300 
2023   75,600 
2024    75,915 
2025    79,380 
2026    72,765 
Thereafter    
-
 
Total undiscounted lease payments    357,960 
Less: Present value discount    (32,462)
Total Present value of lease liabilities   $325,498 

 

8. EQUITY

 

Common Stock and Preferred Stock

 

As of March 31, 2022 and December 31, 2021, the Company’s authorized capital stock consists of 3,000,000,000 shares of common stock, par value $0.001, and 50,000,000 shares of preferred stock, par value $0.001. 1,000 shares of preferred stock are designated as Series A Convertible Preferred Stock. No shares of Series A Preferred Stock are issued and outstanding as of March 31, 2022 and December 31, 2021, respectively. The Company’s Certificate of Designation of Series B Preferred Stock was withdrawn by the Company on June 30, 2020. 1 share of preferred stock is designated Series C Preferred Stock and is issued and outstanding as of March 31, 2022 and December 31, 2021, respectively. The Series C Preferred Stock has a stated value of $24,000 and entitles the holder to 51% of the total voting power of the Company’s stockholders. The Company may, in its sole discretion, redeem the Series C Preferred Stock at any time for a redemption price equal to the stated value. Upon payment of the redemption price by the Company, the Series C Preferred Stock will revert to the status of authorized but unissued preferred stock. 

 

On October 28, 2021, the Company entered into a stock purchase agreement with Danil Pollack (the Company’s then-chief executive officer), and Infinity Management, LLC (“Infinity”). Pursuant to the purchase agreement, upon the closing thereof on November 19, 2021, Mr. Pollack sold to Infinity, 50,000,000 shares of common stock of the Company and one share of Series C preferred stock of the Company for cash consideration of $40,000. The Series C Preferred Stock Infinity acquired represents 51% of the voting power of the Company’s capital stock, and therefore the transaction resulted in a change-in-control of the Company.

 

10

 

 

The purchase agreement further provided for Infinity to make a capital contribution to the Company of $4,792 to cover payment of the amounts due to certain creditors of the Company, as set forth in the purchase agreement. The amount was paid on January 18, 2022.

 

On December 2, 2021, Bespoke Colorado, a newly formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, LLC (“WonderLeaf”), and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the “WonderLeaf Purchase Agreement”). Pursuant to the Wonderleaf Purchase Agreement, Bespoke Colorado agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth in the Wonderleaf Purchase Agreement, for a purchase price of $225,000, to be paid in shares of common stock of the Company (including 2,500,000 shares issuable, and to be held in escrow, upon execution of the Purchase Agreement, and an additional $150,000 of common stock that will be valued based on the volume weighted average price of the common stock, subject to a floor of $0.02 per share and a ceiling of $0.04 per share), provided that, the purchase price for the inventory will be 90% of the wholesale value of the regulated marijuana portion of the inventory and the packaging corresponding thereto set forth on the inventory accounting statement to be prepared pursuant to the Wonderleaf Purchase Agreement, As of the date of filing the Company has not closed on the transaction.

 

On December 14, 2021, the board of directors of the Company adopted the Company’s 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which up to an aggregate of 300,000,000 shares of common stock are available for issuance. Awards under the plan may include options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units, performance share awards, or other equity-based awards, each as defined under the 2021 Plan. Options awarded under the 2021 Plan are to have an exercise price of not less than 100% of the fair market value of the common stock on the grant date and a term of not more than ten years from the option grant date.

 

On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 22,500,000 shares of restricted common stock valued at $675,000 ($0.03 per share), which will vest one year from the date of grant. During the three months ended March 31, 2022 the Company recorded $166,438 of expenses associated with the stock based compensation.

 

On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 45,000,000 shares of restricted common stock valued at $1,350,000 ($0.03 per share), which will vest one year from the date of grant. During the three months ended March 31, 2022 the Company recorded $332,877 of expenses associated with the stock based compensation.

 

During the three months ended March 31, 2022, the Company entered into and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of 39,450,000 shares of common stock and warrants to purchase an aggregate of 9,862,500 shares of common stock, for an aggregate purchase price of $197,250. The warrants have a term of one year and an exercise price of $0.05.

 

Warrants

 

During the three months ended March 31, 2022, the Company entered into and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of 39,450,000 shares of common stock and warrants to purchase an aggregate of 9,862,500 shares of common stock, for an aggregate purchase price of $197,250. The warrants have a term of one year and an exercise price of $0.05.

 

11

 

 

The following table summarizes the warrant activities during the three months ended March 31, 2022:

 

   Number of
Warrants
   Weighted-
Average
Exercise
Price Per
Share
   Weighted-
Average
Remaining
Life
 
Outstanding at December 31, 2021   15,500,000   $0.14   1.15 years 
Granted   9,862,500    0.05   1.0 years   
Canceled or expired   (30,000)   0.40     
Exercised   
-
    
-
     
Outstanding at March 31, 2022   25,332,500   $0.11   0.90 years 
Exercisable at March  31, 2022   25,332,500   $0.11   0.90 years 
Intrinsic value at March 31, 2022       $
-
     

  

Options

 

On December 14, 2021, the Company entered into an employment agreement with Hunter Garth, wherein the Company granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, ten-year options to purchase 15,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. The options were valued at $450,000 using a Black-Scholes pricing model. During the three months ended March 31, 2022 the Company recorded $67,797 of expenses associated with the vesting of these stock options. (See notes 9 and 10).

 

On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, wherein the Company granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, ten-year options to purchase 30,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. The Options were valued at $900,000 using a Black-Scholes pricing model. During the three months ended March 31, 2022 the Company recorded $135,594 of expenses associated with the vesting of these stock options. (See notes 9 and 10).

 

On December 14, 2021 Company issued to a consultant options to purchase 1,000,000 shares of common stock at an exercise price of $0.03. The options vest over a period of 3 months and have life of 10 years. The options were valued at $30,000 using a Black-Scholes pricing model. During the three months ended March 31, 2022 the Company recorded $24,900 of expenses associated with the vesting of these stock options.

  

The following table summarizes the option activities during the three months ended March 31, 2022:

 

   Number of
Options
   Weighted-
Average Exercise
Price Per
Share
   Weighted-
Average
Remaining
Life
 
Outstanding at December 31, 2021   46,072,874   $0.06   9.95 years 
Granted   
-
    
-
  
 
 
Canceled or expired   
-
    
-
     
Exercised   
-
    
-
     
Outstanding at March 31, 2022   46,072,874   $0.06   9.70 years 
Exercisable at March  31, 2022   1,072,874   $0.03   9.44 years 
Intrinsic value at March 31, 2022       $
-
     

 

12

 

 

9. RELATED PARTY TRANSACTIONS

 

On April 21, 2020, Danil Pollack was appointed president, chief executive officer, and chief financial officer of the Company. In connection with Mr. Pollack’s appointment, the Company entered into an employment agreement with Mr. Pollack. Pursuant to the employment agreement, Mr. Pollack agreed to serve as the Company’s chief executive officer and president for a period of one year, which term would renew automatically for successive one year terms, subject to the right of either party to terminate the agreement at any time upon written notice. Mr. Pollack was granted the right, for a period of six months, to purchase up to 100,000,000 shares of common stock of the Company for a purchase price of $0.001 per share.  

 

On September 30, 2020, the Company entered into an amendment to the Company’s employment agreement, dated April 22, 2020, with Danil Pollack, the Company’s then-chief executive officer. Pursuant to the amendment, the Company agreed to pay Mr. Pollack an annual salary of $48,000. On April 27, 2021, the Company entered into an amendment to the Company’s employment agreement with Mr. Pollack. Pursuant to the amendment, the Company agreed to pay Mr. Pollack an annual salary of $66,000 effective April 1, 2021. The Company could also in its discretion pay additional compensation to Mr. Pollack at any time as a bonus. On November 2, 2021, effective July 1, 2021 Mr. Pollack waived all compensation owed to him by the Company as of such date through the date of his resignation as the Company’s chief executive officer. Mr. Pollack elected to forgive $11,000 of salary during four months ended December 31, 2021, and the amount was recorded as a capital contribution.

 

On October 28, 2021, the Company entered into a stock purchase agreement with Danil Pollack, and Infinity Management, LLC. Pursuant to the purchase agreement, upon the closing thereof on November 19, 2021, Mr. Pollack sold to Infinity, 50,000,000 shares of the common stock of the Company and one share of Series C preferred stock of the Company for cash consideration of $40,000. The Series C Preferred Stock Infinity acquired represents 51% of the voting power of the Company’s capital stock, and therefore the transaction resulted in a change-in-control of the Company. The purchase agreement further provided for Infinity to make a capital contribution to the Company of $4,792 to cover payment of the amounts due to certain creditors of the Company, as set forth in the purchase agreement. The amount was paid on January 18, 2022.

 

In connection with the purchase agreement, and effective upon the closing thereunder, Mr. Michael Feinsod, the managing member of Infinity, was appointed as the chief executive officer and chairman of the board of directors of the Company, Mr. Hunter Garth was appointed as a director, as well as chief strategy officer of the Company, and Mr. Pollack resigned from all positions with the Company, including as president, CEO, chief financial officer and director of the Company.  

 

On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 22,500,000 shares of restricted common stock, which will vest one year from the date of grant, and ten-year options to purchase 15,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Garth is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination. (See notes 8 and 10).

  

On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 45,000,000 shares of restricted common stock, which will vest one year from the date of grant, and ten-year options to purchase 30,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Feinsod is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination. (See notes 8 and 10).

 

13

 

 

During the three months ended March 31, 2022, Michael Feinsod, the Company’s chief executive officer, was repaid $2,500.

 

10. COMMITMENTS AND CONTINGENCIES

   

On April 21, 2020, Danil Pollack was appointed president, chief executive officer, and chief financial officer of the Company. In connection with Mr. Pollack’s appointment, the Company entered into an employment agreement with Mr. Pollack. On September 30, 2020, the Company entered into an amendment to the employment agreement. Pursuant to the amendment, the Company agreed to pay Mr. Pollack an annual salary of $48,000. On April 27, 2021, the Company entered into an amendment to the Company’s employment agreement with Mr. Pollack. Pursuant to the amendment, the Company agreed to pay Mr. Pollack an annual salary of $66,000 effective April 1, 2021. The Company may also in its discretion pay additional compensation to Mr. Pollack at any time as a bonus. Mr. Pollack elected to forgive $11,000 of salary during four months ended December 31, 2021; the amount was recorded as a capital contribution. Mr. Pollack resigned on November 19, 2021.

 

In connection with the purchase agreement, a convertible debenture with an original issue date of December 24, 2019, as amended by Amendment No. 1 thereto, dated May 28, 2020, Amendment No. 2 thereto, dated August 21, 2020, Amendment No. 3 thereto, dated December 10, 2020, Amendment No. 4 thereto, dated January 15, 2021, Amendment No. 5 thereto, dated April 2, 2021, and Amendment No. 6 thereto, dated August 2, 2021 (as amended, the “Debenture”) with an original principal amount of approximately $400,000 was terminated, and all amounts due and payable thereunder forgiven pursuant to a cancellation and satisfaction of debenture agreement entered into between the Company and the Debenture holder (the “Debt Cancellation Agreement”). In exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names and agreed to pay the holder, beginning December 1, 2021, and on a monthly basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company (the “Inventory Earn Out”), and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the monthly payments made under the Inventory Earn Out.   (See notes 3 and 6).

  

On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 22,500,000 shares of restricted common stock, which will vest one year from the date of grant, and ten-year options to purchase 15,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Garth is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination. (See notes 8 and 10).

 

On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 45,000,000 shares of restricted common stock, which will vest one year from the date of grant, and ten-year options to purchase 30,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Feinsod is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination. (See notes 8 and 10).

 

11. MAJOR CUSTOMERS

 

At March 31, 2022 and December 31, 2021, no individual customer amounted to over 10% of total accounts receivable. During the three months ended March 31, 2022, one individual customer amounted to over 10% of total sales. During the three months ended March 31, 2021, no individual customer amounted to over 10% of total sales.

 

12. SUBSEQUENT EVENTS 

 

On April 5, 2022, the Company issued and sold to an investor in a private placement 10,000,000 shares of common stock and warrants to purchase 2,500,000 shares of common stock with a term of one year and an exercise price of $0.05, for a purchase price of $50,000

 

On May 16, 2022, the Company issued and sold to an investor in a private placement 1,000,000 shares of common stock and warrants to purchase 250,000 shares of common stock with a term of one year and an exercise price of $0.05, for a purchase price of $5,000.

 

14

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

We and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this report and other filings with the SEC, reports to our stockholders and news releases. All statements that express expectations, estimates, forecasts or projections are forward-looking statements. In addition, other written or oral statements which constitute forward-looking statements may be made by us or on our behalf. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “project,” “forecast,” “may,” “should,” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in or suggested by such forward-looking statements. We undertake no obligation to update or revise any of the forward-looking statements after the date of this report to conform forward-looking statements to actual results, except as may be required under applicable law. Important factors on which such statements are based are assumptions concerning uncertainties, including but not limited to, uncertainties associated with the following:

 

  Inadequate capital and barriers to raising the additional capital or to obtaining the financing needed to implement our business plans;

 

  Our failure to earn significant revenues or profits;

 

  Volatility, lack of liquidity or decline of our stock price;

 

  Potential fluctuation in quarterly results;

 

  Rapid and significant changes in markets;

 

  Insufficient revenues to cover operating costs; and

 

  The effect of the COVID-19 pandemic on our operations, including as it may limit access to our facilities, customers, management, and professional advisors, and negatively impact demand for our products, and ability to raise capital on acceptable terms or at all.  

 

The following discussion should be read in conjunction with the financial statements and the notes thereto which are included in this report.

 

Overview

 

We sell a proprietary line of specially-formulated, premium quality, hemp-derived CBD products direct to consumers through our ecommerce store, found at www.bespokeextracts.com. Information on our website is not part of this report.

 

Under our expanded operating plan, we intend to methodically expand our product offerings to include new flavors, including manuka honey; and introduce additional form factors for our CBD formulations, including lotions and balms, depending on customer feedback and evolving consumer demand.

 

In November 2021, new management of the Company was appointed and the Company began to focus on other complimentary lines of business to its CBD offerings. Under our new management team, we plan to expand the Company’s focus to regulated cannabis markets in the United States.

 

15

 

 

On December 2, 2021, Bespoke Extracts Colorado, LLC, a newly formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the “WonderLeaf Purchase Agreement”). Pursuant to the WonderLeaf Purchase Agreement, Bespoke Colorado agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth in the WonderLeaf Purchase Agreement, for a purchase price of $225,000, to be paid in shares of common stock of the Company (including 2,500,000 shares issuable, and to be held in escrow, upon execution of the WonderLeaf Purchase Agreement, and an additional $150,000 of common stock that will be valued based on the volume weighted average price of the common stock, subject to a floor of $0.02 per share and a ceiling of $0.04 per share), provided that, the purchase price for the inventory will be 90% of the wholesale value of the regulated marijuana portion of the inventory and the packaging corresponding thereto set forth on the inventory accounting statement to be prepared pursuant to the WonderLeaf Purchase Agreement. As of the date of filing the Company has not closed on the transaction.

 

On February 2, 2022, the Company changed its fiscal year from August 31 to December 31.

 

Results of Operations for the three months ended March 31, 2022 and March 31, 2021

 

Sales

 

Sales during the three months ended March 31, 2022 were $3,061 compared to $5,748 for the three months ended March 31, 2021. The decrease in sales was primarily a result of reduced marketing of the Company’s line-up of hemp-derived CBD products and sales of older products at reduced prices.

 

Operating Expenses

 

Selling, general and administrative expenses for the three months March 31, 2022 and three months ended March 31, 2021 were $897,534 and $191,861, respectively. The increase was mainly attributable to stock-based compensation of $727,606 and increase in salaries, partially offset by reduced marketing expenses. Professional fees were $54,355 and $21,343, respectively for the three months ended March 31, 2022 and March 31, 2021. The increase in expenses was due to increased legal and accounting fees associated with the pending Wonderleaf, LLC acquisition. Consulting expense was $23,000 and $71,500, for the three months ended March 31, 2022 and March 31, 2021, respectively. The decrease was primarily due to reduction in consulting expenses for sales and marketing during the three months ended March 31, 2022. Amortization expense of domain names for the three months ended March 31, 2022 and March 31, 2021 was $0 and $811, respectively.

 

Other Income

 

During the three months ended March 31, 2022 there was $181 associated with interest income on the note receivable from Wonderleaf.

 

Net Loss

 

For the reasons stated above, our net loss for the three months ended March 31, 2022 was $972,494, or $0.00 per share, compared to a net loss for the three months ended March 31, 2021 of $281,135, or $0.00 per share

 

Investing Activities

 

During the three months ended March 31, 2022 the Company loaned Wonderleaf a total of $20,000 pursuant to promissory notes, advanced Wonderleaf $6,443 and purchased $7,202 of equipment.

 

Liquidity and Capital Resources

 

As of March 31, 2022, we had cash of $94,331. Net cash used in operating activities for the three months ended March 31, 2022 was $219,793. Our current liabilities as of March 31, 2022 were $241,900 and consisted of accounts payable and accrued liabilities of $105,621, an inventory earn-out of $75,000 and current portion of lease liability of $61,279. As of December 31, 2021, we had cash of $148,227. Net cash used in operating activities for the three months ended March 31, 2021 was $335,499. Our current liabilities as of December 31, 2021 were $220,006 and consisted of accounts payable and accrued liabilities of $82,729, notes payable- related party of $2,500, an inventory earn-out of $75,000 and current portion of lease liability of $59,777.

 

16

 

 

During the three months ended March 31, 2022, the Company repaid $2,500 of a note payable from a related party. In addition, the Company raised a total of $197,250 from the sale of common stock and warrants. During the three months ended March 31, 2021, the Company raised $600,000 from the sale of common stock.

 

The unaudited condensed consolidated financial statements included in this report have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations for the three months ended March 31, 2022 and the year ended December 31, 2021 and had a working capital deficit at March 31, 2022 and December 31, 2021. This raises substantial doubt about our ability to continue as a going concern.

 

We have not generated positive cash flows from operating activities. Our primary source of capital has been from the sale of equity and convertible debt securities. Our primary use of capital has been for professional fees and selling, general and administrative costs. We have no committed sources of capital and will need to raise additional capital to continue and expand our operations. Additional capital may not be available on terms acceptable to us, or at all.

 

In addition, the COVID-19 pandemic may negatively affect our operations, including by limiting access to our facilities, customers, management, and professional advisors, and by causing delays and constraints in manufacturing and shipping of our products. These factors, in turn, may negatively impact our operations, financial condition and demand for our products, and our ability to raise capital on acceptable terms, or at all.

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Critical accounting policies and estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. The more critical accounting estimates include estimates related to revenue recognition and accounts receivable allowances. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described below and in Note 1 to our financial statements appearing elsewhere in this report.

 

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin.

 

17

 

 

Income Taxes

 

We utilize the asset and liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.

 

Stock Based Compensation

 

Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance FASB ASC 718, Compensation-Stock Compensation, including related amendments and interpretations.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Management of the Company conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Based on this evaluation, our management has concluded that the design and operation of our disclosure controls and procedures are not effective since the following material weaknesses exist:

 

  Our chief executive officer also functions as our principal financial officer. As a result, our officer may not be able to identify errors and irregularities in the financial statements and reports;

 

  We were unable to maintain full segregation of duties within our financial operations due to our reliance on limited personnel in the finance function. While this control deficiency did not result in any audit adjustments to our financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties; and

 

  Documentation of all proper accounting procedures is not yet complete.

 

To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned weaknesses, including, but not limited to, increasing the capacity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across the organization and that we have adequate control over financial statement disclosures.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

18

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are not currently a party to, nor are any of our property currently the subject of, any material legal proceedings.

 

Item 1A. Risk Factors.

 

Not required for smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the three months ended March 31, 2022, the Company issued and sold to investors an aggregate of 39,450,000 shares of common stock and warrants to purchase an aggregate of 9,862,500 shares of common stock, for an aggregate purchase price of $197,250. The warrants have a term of one year and an exercise price of $0.05.

 

In connection with the foregoing, we relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

No disclosure required.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

  

Exhibit No.   Description
     
31.1   Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101   Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.*
104   Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.*

 

*Filed herewith.

 

**Furnished herewith.

 

19

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  BESPOKE EXTRACTS, INC.
     
Dated: May 16, 2022 By: /s/ Michael Feinsod
   

Michael Feinsod

Chief Executive Officer

    (Principal Executive Officer,
Principal Financial Officer and
Principal Accounting Officer)

 

20

 

 

633-3738 855 false --12-31 Q1 0001409197 0001409197 2022-01-01 2022-03-31 0001409197 2022-05-16 0001409197 2022-03-31 0001409197 2021-12-31 0001409197 us-gaap:SeriesCPreferredStockMember 2022-03-31 0001409197 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001409197 2021-01-01 2021-03-31 0001409197 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001409197 us-gaap:CommonStockMember 2020-12-31 0001409197 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001409197 bspk:CommonStockPayableMember 2020-12-31 0001409197 us-gaap:RetainedEarningsMember 2020-12-31 0001409197 2020-12-31 0001409197 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001409197 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001409197 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001409197 bspk:CommonStockPayableMember 2021-01-01 2021-03-31 0001409197 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001409197 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001409197 us-gaap:CommonStockMember 2021-03-31 0001409197 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001409197 bspk:CommonStockPayableMember 2021-03-31 0001409197 us-gaap:RetainedEarningsMember 2021-03-31 0001409197 2021-03-31 0001409197 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001409197 us-gaap:CommonStockMember 2021-12-31 0001409197 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001409197 us-gaap:RetainedEarningsMember 2021-12-31 0001409197 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001409197 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001409197 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001409197 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001409197 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001409197 us-gaap:CommonStockMember 2022-03-31 0001409197 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001409197 us-gaap:RetainedEarningsMember 2022-03-31 0001409197 2021-12-02 2021-12-02 0001409197 2021-12-02 0001409197 us-gaap:CommonStockMember 2021-12-02 0001409197 2021-01-01 2021-12-31 0001409197 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001409197 bspk:OptionsMember 2022-01-01 2022-03-31 0001409197 2017-02-21 0001409197 2019-09-01 2020-08-31 0001409197 2019-09-01 2021-08-31 0001409197 bspk:AssetPurchaseAgreementMember 2019-09-01 2021-08-31 0001409197 bspk:AssetPurchaseAgreementMember 2022-01-01 2022-03-31 0001409197 bspk:AssetPurchaseAgreementMember 2021-01-01 2021-03-31 0001409197 pf0:ScenarioForecastMember 2022-08-31 0001409197 pf0:ScenarioForecastMember 2022-08-31 2022-08-31 0001409197 2022-01-10 2022-01-19 0001409197 2022-01-19 0001409197 bspk:WonderLeafMember 2022-03-31 0001409197 2022-02-01 2022-02-08 0001409197 2022-02-08 0001409197 bspk:WonderLeafOneMember 2022-03-31 0001409197 2019-12-24 0001409197 2019-12-01 2019-12-24 0001409197 bspk:SecuritiesPurchaseAgreementMember 2019-09-01 2020-08-31 0001409197 2021-08-02 0001409197 2021-09-01 2021-09-30 0001409197 2021-09-30 0001409197 2021-10-01 2021-10-28 0001409197 2021-12-01 2021-12-02 0001409197 pf0:ScenarioForecastMember 2021-09-01 2022-08-31 0001409197 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001409197 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-03-31 0001409197 pf0:ChiefExecutiveOfficerMember 2021-10-01 2021-10-28 0001409197 2021-12-01 2021-12-07 0001409197 bspk:TwentyTwentyOneEquityIncentivePlanMember 2021-12-01 2021-12-14 0001409197 2021-12-01 2021-12-14 0001409197 us-gaap:RestrictedStockMember bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:HunterGarthMember 2021-12-01 2021-12-14 0001409197 us-gaap:RestrictedStockMember bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:HunterGarthMember 2021-12-14 0001409197 bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:HunterGarthMember 2021-12-01 2021-12-14 0001409197 bspk:HunterGarthMember 2022-01-01 2022-03-31 0001409197 bspk:MichaelFeinsodMember 2022-01-01 2022-03-31 0001409197 us-gaap:RestrictedStockMember bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:MichaelFeinsodMember 2021-12-01 2021-12-14 0001409197 us-gaap:RestrictedStockMember bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:MichaelFeinsodMember 2021-12-14 0001409197 bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:MichaelFeinsodMember 2021-12-01 2021-12-14 0001409197 us-gaap:StockOptionMember bspk:HunterGarthMember 2021-12-01 2021-12-14 0001409197 us-gaap:StockOptionMember bspk:HunterGarthMember 2021-12-14 0001409197 us-gaap:StockOptionMember bspk:HunterGarthMember 2021-12-01 2021-12-13 0001409197 us-gaap:StockOptionMember bspk:HunterGarthMember 2022-01-01 2022-03-31 0001409197 bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:MichaelFeinsodMember 2021-12-14 0001409197 bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:MichaelFeinsodMember 2021-12-01 2021-12-13 0001409197 bspk:TwentyTwentyOneEquityIncentivePlanMember bspk:MichaelFeinsodMember 2022-01-01 2022-03-31 0001409197 us-gaap:WarrantMember 2021-12-31 0001409197 us-gaap:WarrantMember 2022-03-31 0001409197 us-gaap:StockOptionMember 2021-12-31 0001409197 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001409197 us-gaap:StockOptionMember 2022-03-31 0001409197 pf0:ChiefExecutiveOfficerMember 2020-04-01 2020-04-21 0001409197 2020-04-01 2020-04-21 0001409197 bspk:MrPollackMember 2020-09-01 2020-09-30 0001409197 bspk:MrPollackMember 2021-04-01 2021-04-01 0001409197 bspk:MrPollackMember 2021-09-01 2021-12-31 0001409197 bspk:MrPollackMember 2021-11-01 2021-11-19 0001409197 us-gaap:SeriesCPreferredStockMember 2021-11-19 0001409197 2021-11-01 2021-11-19 0001409197 us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-19 0001409197 bspk:HunterGarthMember 2021-12-01 2021-12-14 0001409197 bspk:TwoThousandTwentyOneEquityIncentivePlanMember bspk:MrGarthMember 2021-12-01 2021-12-14 0001409197 bspk:MrGarthMember 2021-12-01 2021-12-14 0001409197 bspk:MrGarthMember 2021-12-01 2021-12-13 0001409197 bspk:MichaelFeinsodMember 2021-12-01 2021-12-14 0001409197 bspk:TwoThousandTwentyOneEquityIncentivePlanMember bspk:MrFeinsodMember 2021-12-01 2021-12-14 0001409197 bspk:MrFeinsodMember 2021-12-01 2021-12-14 0001409197 bspk:MrFeinsodMember 2021-12-01 2021-12-13 0001409197 pf0:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0001409197 bspk:SecuritiesPurchaseAgreementMember 2020-09-01 2020-09-30 0001409197 2021-04-27 2021-04-27 0001409197 2021-09-01 2021-12-31 0001409197 2021-08-02 2021-08-02 0001409197 pf0:ScenarioForecastMember 2022-08-01 2022-08-31 0001409197 bspk:EquityIncentivePlanMember 2021-12-14 0001409197 us-gaap:GrantMember 2021-12-01 2021-12-14 0001409197 us-gaap:CommonStockMember 2021-12-01 2021-12-14 0001409197 us-gaap:CommonStockMember 2021-12-01 2021-12-13 0001409197 pf0:ChiefExecutiveOfficerMember 2021-12-01 2021-12-14 0001409197 bspk:RestrictedCommonStockMember 2021-12-14 0001409197 2021-12-01 2021-12-13 0001409197 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2022-04-05 0001409197 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2022-04-05 0001409197 us-gaap:SubsequentEventMember 2022-04-01 2022-04-05 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure